2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.02E.01 Development of Patient-Derived and Xenograft-Derived Organoids for Lung Adenocarcinoma Study

EP.02E.01 Development of Patient-Derived and Xenograft-Derived Organoids for Lung Adenocarcinoma Study

Pdf Summary

The study by Mr. Wenjie Luo and colleagues from the Department of Surgery at The Chinese University of Hong Kong focuses on the development of patient-derived and xenograft-derived organoids for researching lung adenocarcinoma (LUAD). LUAD is a significant global health issue, and there is a pressing need for advanced preclinical models to better understand and treat this disease. Organoid culture systems have emerged as a promising tool, as they preserve the genetic, transcriptomic, and phenotypic characteristics of the original patient tumors.<br /><br />In this research, experimental models are constructed directly from LUAD patients and xenografts. These models allow for comprehensive phenotypic and genetic profiling of the organoids, which is crucial for developing effective therapeutic strategies. The lung organoids developed in this study exhibit specific morphological characteristics, such as cystic structures with single-layer compartments and densely packed spheroids with thickened walls in the case of LUAD organoids.<br /><br />The study highlights the importance of using organoids to mimic the complex biology of LUAD more accurately, providing a more relevant platform for testing drug responses and understanding tumor behavior. The authors acknowledge the support from the Core Utilities of Cancer Genomics and Pathobiology (CUHK) and thank Winnie W. Y. Cheung for technical assistance.<br /><br />Overall, the development of organoids holds significant potential for advancing LUAD research and therapeutic development, offering a powerful tool to further our understanding of this challenging cancer type and improve patient outcomes.

Asset Subtitle

Wenjie Luo

Meta Tag

Speaker Wenjie Luo

Topic Tumor Biology – Preclinical Biology

Keywords

Wenjie Luo

lung adenocarcinoma

LUAD

organoids

xenograft-derived

patient-derived

preclinical models

therapeutic strategies

genetic profiling

drug responses